+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Recombinant Vaccines Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5786895
Global Recombinant Vaccine Market Report and Forecast 2023-2031
Global Recombinant Vaccine Market Outlook
The value of the global recombinant vaccine market was USD 13.32 billion in 2022, driven by the technological advancements in vaccine development across the globe. The market value is expected to grow at a CAGR of 11.91% during the forecast period of 2023-2031 to reach a value of USD 36.62 billion by 2031.

Recombinant Vaccine: Introduction

Recombinant vaccines are a type of vaccine that is created by inserting a piece of the pathogen's genetic material, typically DNA or RNA, into a carrier virus or bacteria. This carrier is then used to deliver the genetic material into the body, where it triggers an immune response and the body produces antibodies to fight off the pathogen.

Recombinant vaccines are considered a modern and innovative approach to vaccine development, as they offer several advantages over traditional methods of vaccine production. For example, they can be produced more quickly and with greater precision, and they have a lower risk of contamination or adverse reactions.

Recombinant vaccines have been developed for a variety of diseases, including influenza, hepatitis B, human papillomavirus (HPV), and COVID-19. They are considered a promising area of research for the development of new vaccines, particularly for emerging infectious diseases.

Recombinant Vaccine: Application and Uses

Recombinant vaccines are a type of vaccine that is produced through genetic engineering techniques. These vaccines are made using recombinant DNA technology to produce specific antigens, which are then used to stimulate the immune system and create an immune response against a specific pathogen. Recombinant vaccines have a variety of applications, including:
  • Prevention of infectious diseases: Recombinant vaccines are used to prevent infectious diseases such as hepatitis B, human papillomavirus (HPV), and influenza
  • Treatment of cancer: Recombinant vaccines are being developed to treat cancer by stimulating the immune system to target and destroy cancer cells
  • Veterinary medicine: Recombinant vaccines are used to prevent diseases in animals, including livestock and pets
  • Biodefense: Recombinant vaccines are being developed to protect against potential bioterrorism threats, such as anthrax and smallpox
  • Allergies: Recombinant vaccines are used to treat allergies by desensitizing the immune system to specific allergens
Overall, the use of recombinant vaccines is growing due to their safety, effectiveness, and versatility.

Global Recombinant Vaccine Market Segmentations

Market breakup by Type

  • Live Attenuated
  • Subunit

Market breakup by Disease Indication

  • Hepatitis B
  • Rotavirus
  • Herpes Zoster
  • Meningococcal B
  • Others
Market by Distribution Channel
  • Hospitals
  • Vaccination Centres
Market by End User
  • Paediatrics
  • Adults
  • Veterinary

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Global Recombinant Vaccine Market Scenario

The global recombinant vaccine market is expected to witness significant growth in the coming years owing to the increasing prevalence of infectious diseases, technological advancements in vaccine development, and the growing demand for vaccines across the world are some of the key factors driving the growth of the market.

Subunit vaccines are expected to hold the largest share of the market due to their lower risk of side effects and better immunogenicity.

Based on technology, the market is divided into conjugate vaccines, inactivated and subunit vaccines, and live attenuated vaccines. Conjugate vaccines are expected to hold the largest share of the market due to their high effectiveness against various diseases
Based on application, the market is divided into infectious diseases, cancer, and others. Infectious diseases are expected to hold the largest share of the market due to the high prevalence of infectious diseases across the world.

Based on end user, the market is divided into pediatrics, adults, and others. Pediatrics are expected to hold the largest share of the market due to the high demand for vaccines in children.

North America is expected to dominate the market due to the high adoption of advanced vaccines and the presence of major players in the region. However, the Asia Pacific region is expected to witness the highest growth in the coming years due to the increasing prevalence of infectious diseases and the growing demand for vaccines in the region.

Key Players in the Global Recombinant Vaccine Market

The report gives an in-depth analysis of the key players involved in the global recombinant vaccine market. The companies included in the market are as follows:
  • GSK plc
  • Pfizer Inc
  • Sanofi
  • Walvax Biotechnology Co., Ltd. (Walvax)
  • Dynavax Technologies Corporation
  • Merck & Co., Inc
  • Novartis AG
  • GC Biopharma
  • Bayer AG
  • Bharat Biotech
  • Sartorius AG
  • Serum Institute of India Pvt. Ltd
  • Bio Farma

This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Recombinant Vaccine Market Overview
3.1 Global Recombinant Vaccine Market Historical Value (2016-2022)
3.2 Global Recombinant Vaccine Market Forecast Value (2023-2031)
4 Global Recombinant Vaccine Market Landscape
4.1 Global Recombinant Vaccine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Recombinant Vaccine Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Disease Indication
4.2.3 Analysis by Distribution Channel
4.2.4 Analysis by End User
5 Global Recombinant Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Recombinant Vaccine Market Segmentation
6.1 Global Recombinant Vaccine Market by Type
6.1.1 Market Overview
6.1.2 Live Attenuated
6.1.3 Subunit
6.2 Global Recombinant Vaccine Market by Disease Indication
6.2.1 Market Overview
6.2.2 Hepatitis B
6.2.3 Rotavirus
6.2.4 Herpes Zoster
6.2.5 Meningococcal B
6.2.6 Others
6.3 Global Recombinant Vaccine Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Vaccination Centres
6.4 Global Recombinant Vaccine Market by End User
6.4.1 Market Overview
6.4.2 Paediatrics
6.4.3 Adults
6.4.4 Veterinary
6.5 Global Recombinant Vaccine Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Recombinant Vaccine Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Recombinant Vaccine Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Recombinant Vaccine Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Recombinant Vaccine Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Recombinant Vaccine Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Supplier Landscape
17.1 GSK plc
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Pfizer Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Sanofi
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Walvax Biotechnology Co., Ltd. (Walvax)
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Dynavax Technologies Corporation
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Merck & Co., Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 GC Biopharma
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Bayer AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Bharat Biotech
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Sartorius AG
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Serum Institute of India Pvt. Ltd.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Bio Farma
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Recombinant Vaccine Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Gsk plc
  • Pfizer Inc.
  • Sanofi
  • Walvax Biotechnology Co. Ltd. (Walvax)
  • Dynavax Technologies Corporation
  • Merck & Co. Inc.
  • Novartis AG
  • Gc Biopharma
  • Bayer AG
  • Bharat Biotech
  • Sartorius AG
  • Serum Institute of India Pvt. Ltd.
  • Bio Farma



Table Information